EUVIMEDEUVIMED entdecken
Kontrollierte klinische StudieOpen Access · CC BY-NC-ND 4.0

Low‐Dose Baricitinib Plus Narrow‐Band Ultraviolet B for the Treatment of Progressive Non‐Segmental Vitiligo: A Prospective, Controlled, Open‐Label Study

Zhonghui Hu, Lu Lu, Jindi Feng, Hongbin Song, Shiyu Zhang, Lu Yang, Yuehua Liu, Tao Wang iD

Pigment Cell & Melanoma Research · 2025

DOI: 10.1111/pcmr.13209 ↗

Kurz gefasst

Kontrollierte klinische Studie in der Zeitschrift Pigment Cell & Melanoma Research, 2025. Verfasst von Zhonghui Hu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Lab…. Hauptthemen laut MEDLINE: Azetidines, Sulfonamides, Purines, Vitiligo. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National High Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vitiligo is a chronic autoimmune disease, and current treatments for vitiligo have limited efficacy. Janus kinase (JAK) inhibitors could offer new therapeutic options. To evaluate the efficacy and safety of baricitinib, an oral JAK1/2 inhibitor, combined with narrow‐band ultraviolet B (NB‐UVB) in vitiligo treatment. This prospective, controlled, open‐label study included adults with progressive non‐segmental vitiligo (NSV). Patients were assigned to combination therapy with baricitinib 2 mg daily and NB‐UVB three times a week or NB‐UVB alone three times a week (control). The primary endpoint was the proportion of patients achieving 50% or greater improvement from baseline in the total Vitiligo Area Scoring Index (T‐VASI50) at week 16. Of the 33 patients (mean age, 34.1 years; 27.3% women) who completed the study, 12 of 17 (70.6%) patients in the combination group and 2 of 16 (12.5%) in the control group had a T‐VASI50 response at week 16 (relative risk [RR] = 5.6; 95% CI = 1.5–21.4; p = 0.001). Adverse events were minor, including erythema, mild blister after phototherapy and acne. Combination therapy with low‐dose baricitinib and NB‐UVB was effective and well tolerated in adults with progressive NSV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzetidinesSulfonamidesPurinesVitiligoPyrazolesUltraviolet TherapyHumansFemaleAdultMaleProspective StudiesMiddle AgedYoung AdultCombined Modality TherapyTreatment Outcome

Stichwörter der Autor:innen

JAK inhibitorsphototherapyvitiligo

Substanzen

baricitinibAzetidinesSulfonamidesPurinesPyrazoles

Autor:innen und Institutionen

  • Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Researc…
  • Laboratory of Basic Medical Sciences; Department of Dermatology, Qilu Hospital of Shandong University, Jinan, China.

ORCID-Profile: Tao Wang

Förderung

  • National High Level Hospital Clinical Research Funding

Zitieren

APA

Hu, Z., Lu, L., Feng, J., Song, H., Zhang, S., Yang, L., Liu, Y., & Wang, T. (2025). Low‐Dose Baricitinib Plus Narrow‐Band Ultraviolet B for the Treatment of Progressive Non‐Segmental Vitiligo: A Prospective, Controlled, Open‐Label Study. Pigment Cell & Melanoma Research. https://doi.org/10.1111/pcmr.13209

Vancouver

Hu Z, Lu L, Feng J, Song H, Zhang S, Yang L, et al. Low‐Dose Baricitinib Plus Narrow‐Band Ultraviolet B for the Treatment of Progressive Non‐Segmental Vitiligo: A Prospective, Controlled, Open‐Label Study. Pigment Cell & Melanoma Research. 2025. doi:10.1111/pcmr.13209

BibTeX
@article{Hu2025,
  author = {Hu, Zhonghui and Lu, Lu and Feng, Jindi and Song, Hongbin and Zhang, Shiyu and Yang, Lu and Liu, Yuehua and Wang, Tao},
  title = {Low‐Dose Baricitinib Plus Narrow‐Band Ultraviolet B for the Treatment of Progressive Non‐Segmental Vitiligo: A Prospective, Controlled, Open‐Label Study},
  journal = {Pigment Cell & Melanoma Research},
  year = {2025},
  doi = {10.1111/pcmr.13209}
}
Kostenlos starten →